Phase III Study of MDR Modulation With PSC-833 (NSC 648265) Followed by Immunotherapy With rIL-2 (NSC 373364) vs. No Further Therapy in Previously Untreated Patients With AML >60 Years

Trial Profile

Phase III Study of MDR Modulation With PSC-833 (NSC 648265) Followed by Immunotherapy With rIL-2 (NSC 373364) vs. No Further Therapy in Previously Untreated Patients With AML >60 Years

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Dec 2012

At a glance

  • Drugs Valspodar (Primary) ; Aldesleukin; Cytarabine; Daunorubicin; Etoposide; Interleukin-2
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Jun 2008 Results published in the Journal of Clinical Oncology.
    • 10 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top